For patients whose stage III colon cancer carries a particular genetic signature — a deficiency in DNA mismatch repair, known as dMMR — the options after surgery have long been chemotherapy and watchful waiting. The Food and Drug Administration has now approved a new combination: Roche’s Tecentriq, given with its Hybreza formulation alongside standard fluoropyrimidine-and-oxaliplatin chemotherapy, for this group of patients.
The approval rests on the ATOMIC trial, and on a number oncologists tend to notice. The combination cut the risk reflected in its primary measure by half (a hazard ratio of 0.50), and three-year disease-free survival reached 86.3 percent against 76.2 percent for chemotherapy alone. In plain terms: among patients whose cancers are most likely to recur after surgery, substantially more of them remained disease-free three years on when immunotherapy joined the regimen.
The biology explains the bet. Mismatch-repair-deficient tumours accumulate mutations at an unusual rate, which makes them more visible to the immune system — the very visibility checkpoint inhibitors like Tecentriq are designed to exploit. That is why the dMMR subtype, a minority of colon cancers, has become one of immunotherapy’s most closely watched testing grounds, and why trial leaders such as the Mayo Clinic’s Frank Sinicrope have argued these patients should be studied as their own population rather than averaged into the whole.
Roche’s oncology leadership, including chief medical officer Levi Garraway, framed the approval as a template: find the molecular subset, prove the benefit there, and bring immunotherapy forward from last-resort treatment into the curative-intent setting where it can change the most lives. Regulators, with this decision, have endorsed exactly that sequence for stage III dMMR disease.
For patients, the practical questions follow quickly — eligibility testing for dMMR status, availability, and how the combination’s side-effect burden weighs against a halved recurrence risk. Those are conversations for clinic rooms. But the direction of the field is now official policy: colon cancer treatment after surgery is being rebuilt, subtype by subtype, and this week’s approval is one of its load-bearing walls.
Related reading: CDC Data Trace a Rare Brain Fungus Moving the Wrong Way · A Paused Hepatitis B Study, a Restart, and a Fight Over What Counts as Ethical · A Year of NAD Boosters, and Parkinson's Did Not Budge
